Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751533 | 0.90 | TSHR (0.45) | TSHRSMN1; SMN2HPGDLMNAP2RX7 | |
| SCHEMBL1752274 | 0.88 | TSHR (0.43) | TSHRSMN1; SMN2HPGDP2RX7 | |
| SCHEMBL3089010 | 0.88 | TSHR (0.43) | TSHRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1751211 | 0.85 | EPHX2 (0.48) | TSHRSMN1; SMN2HPGDP2RX7ALDH1A1 | |
| SCHEMBL1751254 | 0.85 | P2RX7 (0.44) | TSHRSMN1; SMN2HPGDLMNAP2RX7 | |
| SCHEMBL3093509 | 0.83 | HTR7 (0.41) | TSHRSMN1; SMN2P2RX7 | |
| SCHEMBL3092964 | 0.81 | HTR1A (0.43) | TSHRSMN1; SMN2 | |
| SCHEMBL1750509 | 0.81 | KDM4E (0.46) | SMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL3088565 | 0.78 | PRMT5 (0.47) | P2RX7 | |
| SCHEMBL1751380 | 0.78 | TRPV1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | BEZENCON OLIVIER | 2010-12-23 | — | — | US | disclosed |
| US-7799805-B2 | Piperidine carboxylic acid amide derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| EP-1981847-A1 | SECONDARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-04 | — | — | US | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | REN, ACE, AGTR2 | TSHR 3578/4885SMN1; SMN2 4649/4885HPGD 429/4885 |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | REN, ACE, AGTR2 | TSHR 3666/4885SMN1; SMN2 4592/4885HPGD 494/4885 |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | TSHR 1994/4885SMN1; SMN2 4441/4885HPGD 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.